NASDAQ · Analyst Forecast

First Tracks Biotherapeutics, Inc. (TRAX) Stock Forecast & Price Target

$43.57 NASDAQ: TRAX Market Cap $1.83B

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 16, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering First Tracks Biotherapeutics, Inc. (TRAX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For First Tracks Biotherapeutics, Inc., the average estimate for 2030 earnings per share is −$4.50; 8 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$43.57
Consensus targetThe average of the price targets analysts have published.$72.44
Median targetThe middle target, less affected by a single outlier.$65.00
Highest targetThe most optimistic published target.$110.00
Lowest targetThe most pessimistic published target.$57.00
Difference from priceHow far the consensus target sits from today’s price.+66.3%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$0$0$03
2026$75.00M$75.00M$75.00M6
2027$0$0$07
2028$0$0$08
2029$20.98M$20.98M$20.98M6
2030$32.90M$32.90M$32.90M6

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$4.85−$4.85−$4.853
2026−$4.28−$3.99−$3.856
2027−$4.30−$3.46−$2.487
2028−$4.62−$3.78−$2.818
2029−$3.86−$3.86−$3.866
2030−$4.50−$4.50−$4.506

First Tracks Biotherapeutics, Inc. (TRAX) forecast — frequently asked questions

What is the analyst price target for First Tracks Biotherapeutics, Inc.?

Analysts covering First Tracks Biotherapeutics, Inc. (TRAX) have a consensus price target of $72.44, 66.3% above the current price of $43.57. Published targets range from $57.00 to $110.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for First Tracks Biotherapeutics, Inc.'s earnings?

The average analyst estimate for First Tracks Biotherapeutics, Inc. (TRAX) earnings per share in 2030 is -4.50, with individual estimates between -4.50 and -4.50.

How much revenue is First Tracks Biotherapeutics, Inc. expected to make?

Analysts forecast First Tracks Biotherapeutics, Inc. (TRAX) revenue of $32.90M in 2030, based on 6 published estimates.

How many analysts cover TRAX?

8 analysts contribute estimates for First Tracks Biotherapeutics, Inc. (TRAX). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.